Last reviewed · How we verify
F-18 florbetapir PET
F-18 florbetapir PET, marketed by Brigham and Women's Hospital, is a diagnostic imaging agent used in positron emission tomography (PET) scans. The key composition patent expires in 2028, providing a period of market exclusivity. The primary risk is the lack of revenue data, which may indicate limited commercial success or market penetration.
At a glance
| Generic name | F-18 florbetapir PET |
|---|---|
| Also known as | F-18 labeled Florbetapir (Trade Name: Amyvid) |
| Sponsor | Brigham and Women's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Alzheimer's Disease Neuroimaging Initiative 4
- Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis (PHASE1, PHASE2)
- Biomarker Exploration in Aging, Cognition and Neurodegeneration (PHASE3)
- Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography (PHASE4)
- Molecular Imaging of Primary Amyloid Cardiomyopathy (NA)
- A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau (PHASE1)
- Effects of Brain Beta-Amyloid on Postoperative Cognition (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F-18 florbetapir PET CI brief — competitive landscape report
- F-18 florbetapir PET updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI